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Background: Gliomas are the most common types of primary brain tumors in the adult central nervous system.
TMEM140 is identified as an amplified gene in the human gastric cancer genome. However, the function of TMEM140
in gliomas has not been thoroughly elucidated. The aim of the current study was to determine the clinical significance
of TMEM140 expression in patients with gliomas and its effect on tumor cell malignant phenotypes.
Methods: Immunohistochemical analysis and real-time reverse transcription PCR were performed to detect the
expression levels of TMEM140 in 70 glioma brain tissue samples. Next, the correlation between the TMEM140
expression levels and the clinical characteristics and outcomes of glioma patients was statistically analyzed. TMEM140
expression was inhibited in two glioma cell lines (i.e., U87 and U373) using a knockdown method with small interfering
RNA. Cell Counting Kit-8 and Transwell assays were used to investigate TMEM140 function during cell proliferation,
invasion, and migration, respectively. Using flow cytometry and Western blot analysis, we subsequently determined the
cell cycle and apoptosis profile of the TMEM140-silenced cells.
Results: TMEM140 protein expression was significantly higher in gliomas than in normal brain tissues (p < 0.0001).
TMEM140 overexpression was strongly correlated with tumor size, histologic grade, and overall survival time (P < 0.05).
TMEM140 decreased cell viability in vitro and dramatically decreased tumor volume in vivo. This phenomenon might
be caused by G1 phase cell cycle arrest and cell apoptosis. TMEM140 silencing could suppress the viability, migration,
and invasion of glioma cells.
Conclusions: Our results suggest that TMEM140 expression is a prognostic factor that might play an important role in
the viability, migration, and invasion of glioma cells. This study highlights the importance of TMEM140 as a novel
prognostic marker and as an attractive therapeutic target for gliomas.
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Gliomas, which arise from glia cells, are the most com-
mon type of primary tumors in the central nervous
system. Malignant glioma is classified as grade II–IV ac-
cording to the 2007 World Health Organization (WHO)
classification system [1]. Malignant glioma is a leading
cause of death in patients, accounting for 45–55 % of pri-
mary intracranial tumors. The annual incidence of malig-
nant glioma is greater than 5 per 100,000 population [2].
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creativecommons.org/publicdomain/zero/1.0/biologically aggressive malignant glioma. It is characterized
by the hallmark features of unrestrained cellular prolifera-
tion, strong resistance to apoptosis, diffuse infiltration, vig-
orous angiogenesis and widespread genomic instability.
With advances in aggressive surgery, radiation, and chemo-
therapy, the clinic survival rate for glioma has been greatly
improved [3–5]. However, the median survival rate of pa-
tients with GBM remains less than 1 year [6, 7]. Under-
standing the molecular mechanisms involved in the
formation and development of glioma is important for pre-
venting and treating glioma and improving patient survival.
Numerous molecular abnormalities, such as gene sequence
alterations, DNA copy-number changes, chromosomal re-
arrangements, DNA methylation, and abnormal regulationdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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tumorigenesis and development of glioma [8]. Inactivation
of the Rb and p53 pathway [9–11], activation of receptor
tyrosine kinases (RTKs) [8], and EGFRvIII activity [12],
which are involved in tumor cell adhesion, migration, inva-
sion, proliferation, and apoptosis, are observed in glioma
[13–16]. However, the exact mechanism associated with
this relationship remains unclear [15].
Transmembrane protein 140 (TMEM140, also known
as FLJ11000) is a 185 amino acid protein encoded by a
gene that maps to chromosome 7q33. Few studies have
investigated the functions of this protein. Guan et al. re-
ported an inhibitory effect of TMEM140 on herpes simplex
virus 1 (HSV-1) proliferation [17]. Although TMEM140
has been identified as an amplified gene in the human gas-
tric cancer genome [18], to the best of our knowledge,
there have been no reports describing the functions of
TMEM140 in tumorigenesis and development of tumors.
The present study demonstrated the overexpression of
TMEM140 in glioma tissues and analyzed the prognostic
significance of TMEM140 expression in a large number of
patients with gliomas. Next, we then investigated the ef-
fects of TMEM140 knockdown on cell viability and inva-
sion in vitro and in vivo. Furthermore, we explored theFig. 1 TMEM140 was overexpressed in glioma and was negatively correlate
TMEM140-specific antibody (brown staining), as described in “Material and
glioma and normal brain tissues. c TMEM140 expression was significantly in
the patients (n = 10) from the TCGA GBM dataset (P < 0.0001). Survival anal
GBM dataset (e, P < 0.01) and GSE16011 dataset (f, P < 0.05)underlying mechanisms. Our data suggest that TMEM140
can be a novel prognostic factor and potential treatment
target for gliomas.
Results
Overexpression of TMEM140 and its prognostic
significance in glioma patients
To investigate the protein expression profile of TMEM140
in gliomas, immunohistochemistry (IHC) was used in 70
formalin-fixed, paraffin-embedded tissue sections and 14
non-neoplastic brain tissues. As shown in Fig. 1a,
TMEM140 can be observed in 67.1 % (47/70) of the glioma
specimens. Note that the control brain tissues had lower
expression levels of TMEM140 protein compared with the
glioma tissues.
We quantified the expression level of TMEM140 in
glioma tissues compared with the control brain tissues
(60 gliomas and 14 controls) using real-time reverse
transcription PCR (RT-PCR) analysis. As shown in Fig. 1b,
the level of TMEM140 in the tumor tissues was signifi-
cantly higher than that in the controlled brain tissues
(2.21 ± 0.11 vs. 0.87 ± 0.07, respectively, P < 0.0001). Next,
we reanalyzed the high throughput RNA-sequencing data
from the GBM cohort of the Cancer Genome Atlasd with patient survival. a IHC staining of human glioma tissues using
methods” section. b Quantification of TMEM140 mRNA expression in
creased in glioma tissues (n = 529) compared with normal tissues from
ysis of patients using our own data (d, P < 0.05), as well as the TCGA
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significantly increased in glioma tissue compared with
normal brain tissue (Fig. 1c, P < 0.001).
The relationship between the clinicopathologic features
and TMEM140 protein expression levels in 70 glioma pa-
tients is summarized in Table 1. A chi-square test showed
that the increased expression level of TMEM140 was sig-
nificantly correlated with tumor size (P = 0.0211) and
pathological grade (P = 0.0108). As shown in Table 1, there
was no correlation between the expression level of
TMEM140 protein and patient age or gender.
Therefore, we analyzed the relationship between
TMEM140 protein overexpression and patient prognosis.
A Kaplan-Meier survival curve was used to analyze
the prognostic significance of TMEM140 expression.
TMEM140 expression was divided into high-expression
and low-expression groups. It was observed that patients
with gliomas expressing high levels of TMEM140 sho
wed statistically poorer prognoses compared with pa-
tients with gliomas expressing low levels of TMEM140-
(P = 0.019; Fig. 1d). Furthermore, analyses of the TCGA
GBM (https://tcga-data.nci.nih.gov/tcga/tcgaCancerDetails.
jsp?diseaseType=GBM&diseaseName=Glioblastoma%20
multiforme) and GSE16011 datasets [18] (http://www.
ebi.ac.uk/arrayexpress/experiments/E-GEOD-16011/?query=
GSE16011) also showed that patients with high TMEM140
protein expression had a significantly shorter overall sur-
vival rate time (TCGA, P = 0.008; GSE16011, P = 0.016;
Fig. 1e, f ).
TMEM140 silencing suppressed the growth of glioma
cells in vitro and in vivo
To address the efficacy of TMEM140 on glioma cells,
we knocked down TMEM140 in the glioma cell lines.
We evaluated the expression levels of TMEM140 in five
glioma cell lines (i.e., U87, U251, SHG44, U373, and
T98G) through RT-PCR and Western blot analysis
(Fig. 2a). Two cell lines (U87 and U373) that showedTable 1 Correlation of TMEM140 expression in human glioma
patients with different clinicopathological features (n = 70)
Parameters Characteristic TMEM140 P value
High (n = 47) Low (n = 23)
Age (years) ≥55 27 13 0.6164
<55 18 12
Gender Male 16 10 0.5990
Female 31 13
Tumor size ≥4.5 cm 20 17 0.0211*
<4.5 cm 27 6
WHO grade I/II 15 15 0.0108*
III/IV 32 8
WHO World Health Organization
*P<0.05higher TMEM140 mRNA and protein expression levels
were selected for RNA interference experiments. As
shown in Fig. 2b, c, all three TMEM140 small interfering
RNA (siRNA) sequences showed efficient silencing of
TMEM140 expression based on Western blot and RT-
PCR analyses. TMEM140-RNAi-2 was the most effective
protein, and it was used for the following assays.
Cell growth analysis was performed for two glioma cell
lines (U87 and U373) transfected with TMEM140-
RNAi-2, which were then subjected to cell growth ana-
lysis. In a cell viability assay, both glioma cell lines
showed significant reductions in cell viability through
TMEM140 silencing compared with normal control cells
(Fig. 3a, b). Seventy-two hours after siRNA transfection,
cell viability was reduced 42.3 and 36.8 % in the U87
and U373 cells, respectively.
We also found that the in vivo tumor growth and
weight in the TMEM140-RNAi group were strongly
inhibited compared with the normal control group
(Fig. 3c, d). At the end point, the tumor volumes were
498.4 ± 62.0 and 1145.1 ± 145.4 mm3 in the TMEM140-
RNAi and normal control groups, respectively (P < 0.01).
Furthermore, the tumor weights were 0.44 ± 0.04 and
0.24 ± 0.04 g in the TMEM140-RNAi and normal control
groups, respectively (P < 0.01). Therefore, these findings
showed that TMEM140 was required for the growth of
glioma cells both in vitro and in vivo.
To address the mechanism underlying the growth sup-
pression of glioma cells by TMEM140 knockdown, we
then determined the cell cycle profile (Fig. 3e) of the
TMEM140-silenced cells through flow cytometry. The
results showed that TMEM140 silencing increased the
population of the U87 and U373 cells in the G0/G1
phase by 53.5 and 43.3 %, respectively (P < 0.001).TMEM140 silencing caused apoptosis in the glioma cells
To probe the TMEM140-associated pathways in an
unbiased manner, we performed Gene Set Enrichment
Analysis (GSEA) based on the TCGA GBM dataset.
We found that the KEGG apoptosis pathway (Fig. 4a)
and cell adhesion molecules (Fig. 5a) were identified
with the strongest association with higher TMEM40
expression levels.
The effect of TMEM140 on apoptosis in glioma cells
(Fig. 4b) was investigated. TMEM140 knockdown in the
glioma cells induced cell apoptosis at approximately 12-
fold the rate in the corresponding normal control cells.
Moreover, three apoptotic regulation factors [19] (i.e.,
Bcl2, Bax, and cleaved caspase3) were evaluated using
Western blot analysis. TMEM140 deficiency caused the
up-regulation of the proteins promoting apoptosis (Bax
and cleaved caspase3) and the down-regulation of the
protein inhibiting apoptosis (Bcl2) (Fig. 4c, d).
Fig. 2 Suppressing of TMEM140 expression by RNAi. a TMEM140 expression level in five glioma cell lines was analyzed by RT-PCR (left) and immunoblot
(middle and right). b, c The effect of TMEM140 knockdown through siRNA silencing. The cells were transfected with normal control or TMEM140-RNAi for
48 h and then subjected to RT-PCR (left) and immunoblot analysis (middle and right) of the TMEM140 expression level. The representative
images for immunoblot are shown in the middle panel, and data from three independent experiments were expressed as the mean ± S.D.
(right panel). Wild type: wild-type cells; normal control: scrambled siRNA transfected cells; RNAi-1, RNAi-2, and RNAi-3: TMEM140-RNAi-1, -2,
and -3 transfected cells (*P < 0.05, **P < 0.01, ***P < 0.001 compared with normal control)
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and invasion of glioma cells
Next, we next investigated the effects of TMEM140 on
cell adhesion, migration, and invasion. TMEM140 knock-
down decreased the adherent U87 and U373 cells by 61.5
and 43.3 %, respectively (Fig. 4b). TMEM140 knockdown
strongly inhibited cell motility, with fewer than 60 % of
the U87 and U373 cells migrating (Fig. 4c). In contrast to
the normal control cells, the invasive ability of the
TMEM140 knockdown cells was greatly reduced (Fig. 4d).
The number of invaded U87 and U373 cells with
TMEM140 silenced was 35.9 % compared with 42.9 % for
the normal control cells.
In contrast with the normal control cells, knockdown
TMEM140 caused significantly down-regulated cell ad-
hesion molecules (ICAM1, VCAM1, and Syndecan1) in
the U87 and U373 cells. This finding is also consistent
with functional characterization in vitro.
Discussion
TMEM140 gene is located on chromosome 7, and alter-
ations of chromosome 7 are closely related to various
cancers [20–25], such as breast cancer, prostate cancer,
and gliomas. It remains unclear whether TMEM140 has
important biological functions in tumors. In the presentstudy, we found that TMEM140 was frequently overex-
pressed in 67.1 % (47/70) of the glioma tissues. We hypoth-
esized that the overexpression of TMEM140 may promote
tumor cell growth in gliomas. To test this hypothesis, we
examined the expression status of TMEM140 and the clini-
copathologic features, as well as the biological significance
of its expression in glioma cell lines. Consequently, the re-
sults implied that large tumor size, high histologic grade,
and low patient survival rates were associated with high
TMEM140 expression levels. Moreover, down-regulation of
TMEM140 expression suppressed cell proliferation, migra-
tion, and invasion in two glioma cell lines (U87 and U373),
which indicated that TMEM140 could be a potential thera-
peutic target of gliomas and warrants further investigation.
Unstrained cell proliferation is one of the most remark-
able features of malignancies. Abnormal regulation in cell
cycle and cell apoptosis frequently results in aberrant cell
proliferation in cancer [26–29]. Here, the silencing of
TMEM140 by siRNA transfection significantly induced
G1-phase arrest (Fig. 3e) and cell apoptosis (Fig. 4), which
may trigger the inhibitory effects of TMEM140 siRNA on
cell proliferation in vitro and in vivo.
Cell adhesion, migration, and invasion are key steps for
tumorigenicity in tumor progression [26, 30–32]. Based
on GSEA of the TCGA GBM dataset, we found that
Fig. 3 (See legend on next page.)
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Fig. 3 The growth-suppressive effect of TMEM140 silencing on GBM cells in vitro and in vivo. a, b The cells were transfected with TMEM140-RNAi-2 or
normal control and then subjected to cell proliferation assay by CCK-8. TMEM140 knockdown via siRNA silencing inhibited the proliferation of U87 (a)
and U373 (b) cells. c, d TMEM140 knockdown inhibited the growth of U87 cells in vivo. The representative images for xenograft tumor on the nude
mouse are shown in Fig. 1d (top panel), and the tumor growth curve or tumor weight is shown in Fig. 1c, d (n = 5). e U87 and U373 cells were
transfected with the indicated siRNA. Cells were collected after 48 h, and cell cycle profile was analyzed using flow cytometry. The representative
images are shown in the left panel, and data from three independent experiments are expressed as the mean ± S.D. (right panel) (*P < 0.05, ** P < 0.01,
***P < 0.001 compared with normal controls)
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cules (Fig. 5a), which have been implicated in tumor pro-
gression. In addition, our in vitro data demonstrated that
the depletion of TMEM140 significantly suppressed cell
adhesion, migration, and invasion (Fig. 5b–d). Further-
more, TMEM140 knockdown remarkably decreased the
protein levels of ICAM1, VCAM1, and Syndecan1
(Figs. 5e, f ), which are considered to be important in gli-
oma cell migration and invasion [33]. These data provided
useful information explaining how TMEM140 siRNA
inhibited glioma cell migration and invasion, although
more in-depth studies are necessary.
Conclusion
In conclusion, we found for the first time that TMEM140
accumulates in gliomas. The higher level of TMEM140 isFig. 4 Depletion of TMEM140-induced apoptosis of glioma cells. a GSEA was
positive associated with TMEM140 higher expression. b U87 and U373 cells w
labeled with Annexin V-FITC and PI, and analyzed using flow cytometry. c, d T
Bcl2) were evaluated by western blot analysis. The representative images are
are expressed as the mean ± S.D. (right panel) (*P < 0.05, ** P < 0.01, ***P < 0.0strongly correlated with tumor size, histologic grade, and
overall survival time in this disease. TMEM140 silencing
could suppress the viability, migration, and invasion of gli-
oma cells. Our data demonstrated that TMEM140 is not




A total of 70 patients with glioma were enrolled in this
study. The patients underwent surgical removal of their
tumors at Xinhua Hospital, Shanghai Jiaotong University
School of Medicine, Shanghai, China, from January 2009
to December 2010. All patients had intracranial gliomas
and no history of other malignancies. Histological sec-
tions of the primary resected surgical specimens wereperformed using the TCGA GBM dataset. The cell apoptosis pathway was
ere transfected with indicated siRNA. Cells were harvest after 48 h, double
he expression levels of three apoptotic factors (cleaved caspase, Bax and
shown in the left panel, and data from three independent experiments
01 compared with the normal controls)
Fig. 5 (See legend on next page.)
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Fig. 5 TMEM140 silencing suppressed adhesion, migration, and invasion in the glioma cells. a Based on the TCGA GBM dataset, GSEA showed
that KEGG cell adhesion molecules were positively associated with higher TMEM140 expression levels. The cells were transfected with normal
control or TMEM140-RNAi for 48 h and subjected to cell adhesion, migration, and invasion assay. b TMEM140 knockdown inhibited glioma cell
adhesion. c TMEM140 knockdown inhibited the migration abilities of glioma cells. d TMEM140 knockdown suppressed the invasive abilities of
the glioma cells. The representative images are shown in the upper panel, and data from three independent experiments are expressed as the mean ±
S.D. e, f Expression levels of cell adhesion molecules, ICAM1, VCAM1, and Syndecan1 were evaluated by Western blot analysis (lower panel). (*P < 0.05,
**P < 0.01, ***P < 0.001 compared with the normal controls)
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2007 WHO Classification of Tumors of the Central Ner-
vous System [1]. The patients’ clinical characteristics, such
as age, gender, and tumor size, were collected for statistical
analysis. All patients had complete 5-year follow-ups until
death or until the last follow-up. Overall survival time was
calculated from the date of the initial surgical operation
until death. Additionally, 14 non-neoplastic brain tissue
samples were obtained from surgical procedures for epi-
lepsy. The study protocol was approved by the local, inde-
pendent ethics committee at Xinhua Hospital, Shanghai
Jiaotong University School of Medicine. Written informed
consent was obtained from all patients.
Cell culture
The human glioblastoma cell lines (U87, U251, SHG44,
U373, and T98G) were purchased from the Cell Bank of
the Shanghai Branch of the Chinese Academy of Sci-
ences (Shanghai, China). All culture media were supple-
mented with 10 % fetal bovine serum (FBS, Hyclone,
Logan, UT, USA) and 100 U/mL penicillin/streptomycin
(Gibco, Carlsbad, CA, USA). U87, U373, and T98G were
cultured in Eagle’s Minimum Essential Medium (MEM,
Hyclone), while the U251 and SHG44 cells were cul-
tured in Dulbecco’s Modified Eagle’s medium (DMEM,
Hyclone). All cell lines were maintained in a humidified
atmosphere, with 5 % CO2 at 37 °C.
Gene silencing
Two glioma cell lines, U87 and U373, were transfected
with siRNA oligonucleotides using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA). Briefly, siRNA and Li-
pofectamine 2000 were incubated separately with Opti-
MEM for 5 min and mixed together for 20 min at room
temperature, and then the mixture was applied to cells
plated in 4 mL of medium (final concentration of siRNA,






GACUU-3′;and normal control scrambled siRNA, 5′- UUGUAC
UACACAAAAGUACUG-3′.
All siRNAs were purchased from GenePharma (Shanghai,
China).
Immunohistochemical analysis
Tissues, 5-μm sections, were dehydrated and sub-
jected to antigen retrieval and endogenous peroxidase
blocking. The sections were subsequently incubated
with TMEM140-specific antibody (Abcam, Cambridge,
MA, USA) overnight at 4 °C followed by incubated
with goat anti-rabbit secondary antibody, and the sec-
tions were subsequently developed using 3,3-diamino-
benzidine (DAB) solution and counterstained with
hematoxylin. The staining assessments were per-
formed by two senior neuropathologists who were
blinded to the clinical parameters. The specimens
were graded into two groups, according to the extent
of positivity, as follows: low, <25 % of the tumor cells
showed positive stain; and high, >25 % of tumor cells
showed positive stain.
Real-time reverse transcription PCR (RT-PCR)
Total RNA was extracted from the glioma and normal
brain tissues or from the cell lines using TRIzol reagent
(Invitrogen), according to the manufacturer’s instruc-
tions. DNase I-treated RNA was reverse transcribed
using a first-strand cDNA synthesis kit (Fermentas, Han-
over, MD, USA). Each cDNA was amplified using a
standard SYBR Green kit (Thermo Fisher Scientific,
Rockford, IL, USA) and then loaded into the 7300 RT-
PCR Detection System (Applied Biosystems, Foster City,
CA, USA). The thermal cycling conditions were as fol-
lows: 95 °C for 10 min for the first step, and then for en-
suing 40 cycles, 95 °C for 15 s and 60 °C for 45 s. The





forward primer: 5′-AATCCCATCACCATCTTC-3′; and
reverse primer: 5′-AGGCTGTTGTCATACTTC-3′.
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Cell lysates were extracted with RIPA cell lysis buffer, and
the protein concentration in the lysates was quantified
using an enhanced bicinchoninic acid protein assay kit
(Thermo Fisher Scientific). Protein samples (30–50 μg)
were loaded for immunoblotting using antibodies against
TMEM140, Bcl2, Bax, intercellular adhesion molecule 1
(ICAM1), vascular cell adhesion molecule1 (VCAM1) and
Syndecan1 (Abcam, Cambridge, MA, USA), and GAPDH
(Cell Signaling Technology, Danvers, MA, USA). Specific
proteins were detected with enhanced chemiluminescence
(ECL, Millipore, Bredford, USA). Band density was mea-
sured (ImageJ software) and normalized to GAPDH.
Tumor formation assay
Five-week-old male athymic nude mice were purchased
from the Shanghai Experimental Animal Center. U87
cells transfected with TMEM140-siRNA or the control
siRNA for 24 h were trypsinized, resuspended in PBS,
and then subcutaneously injected into the flank of nude
mice with 2 × 106 cells per injection (n = 5 per group).
Tumor size was measured with a Vernier caliper every
4 days and calculated as (length × width2)/2. All proce-
dures were performed in accordance with the National
Institutes of Health Guide for the Care and Use of La-
boratory Animals.
Cell viability assay
Cell viability was assayed using the Cell Counting Kit-8
(CCK-8, Dojindo Laboratories, Tokyo, Japan) according
to the manufacturer’s instructions. Briefly, treated and
untreated cells were seeded in 96-well plates at a density
of 1000–1500 cells per well and incubated for 1, 2, or
3 days. At the indicated time point, the CCK8 solution
was added to each well and incubated for 1 h. The ab-
sorbance value (optical density) of each well was measured
at 450 nm. For each experimental condition, three wells
were used. All experiments were performed in triplicate.
Evaluation of cell cycle distribution and cell apoptosis by
flow cytometry
Treated and untreated cells were harvested and fixed in
70 % ethanol at −20 °C overnight. Fixed cells were then
washed in PBS and stained with 0.1 mg/ml propidium
iodide (PI, Sigma, St. Louis, MO, USA) containing 1 mg/
ml RNase A for 30 min at 37 °C. Intensities of fluores-
cence signals were measured on a FACScan flow cyt-
ometer (BD Biosciences, San Jose, CA, USA). The
percentages of cells in the G0/G1, S, and G2/M phases
were determined using FlowJo software (Tree Star). All
experiments were performed three times.
The percentage of cells actively undergoing apoptosis was
determined by double staining with Annexin V-fluorescein
isothiocyanate (FITC) and PI. Transfected cells wereharvested, double-labeled with Annexin V-FITC and PI
apoptosis detection kits (KeyGEN Biotech, Nanjing, China),
and analyzed using a FACScan flow cytometry. At least
20,000 cells were acquired for each sample. The experi-
ments were performed in triplicate.
Cell adhesion assay
Treated and untreated cells were seeded onto fibronectin-
coated 12-well plates at a density of 1 × 105 cells per well
and allowed to adhere at 37 °C for 1 h. After the non-
adherent cells were washed with a PBS, the attached cells
were fixed in 4 % paraformaldehyde and stained with
GIEMSA solution. The adherent cells were photographed
and counted under an Olympus inverted microscope
(Lake Success, NY, USA). The experiments were per-
formed in triplicate.
Cell migration and invasion assays
In vitro cell migration and invasion assays were per-
formed using 24-well Transwell chambers (8-μm pores,
Coring Incorporated, NY, USA). The treated and un-
treated cells were cultured in the top chamber with
serum-free media in triplicate at 5 × 104 cells per well. In
the lower chamber, 500-μl media with 10 % FBS was
added as a chemoattractant. After 24 h of cultivation,
the media from the chamber and the Transwell were re-
moved, and the chamber was gently wiped with a cotton
swab. The migrated cells were fixed in 4 % paraformal-
dehyde, stained with crystal violet solution and counted
under a microscope in five fields (×200). The procedure
for the cell invasion assay was similar to the cell migra-
tion assay, except that the Transwell membranes were
precoated with Matrigel (BD Biosciences).
Gene Set Enrichment Analysis (GSEA)
Glioblastoma multiforme (GBM) cohort downloaded
from The Cancer Genome Atlas (TCGA) was analyzed
by GSEA. GSEA was performed using GSEA software,
Version 2.0.1, which was obtained from the Broad Insti-
tute (http://www.broad.mit.edu/gsea; ref. 20), as previ-
ously described [34–37]. Gene set permutations were
performed 1000 times for each analysis. The nominal
P value and normalized enrichment score (NES) were
used to sort the pathways enriched in each phenotype.
Statistical analysis
All statistical analyses were performed using the SPSS 16.0
software package. Data are presented as the mean ± S.D. A
two-tailed Student’s t-test was used for between-group
comparisons. The correlation between the IHC staining
score and clinicopathologic variables was evaluated using a
chi-squared test. Kaplan-Meier survival curves were
calculated using death as the end point. The difference
in the overall survival curves was examined with a log-
Li et al. Journal of Hematology & Oncology  (2015) 8:89 Page 10 of 11rank test. Differences were considered to be statistically
significant at P < 0.05.
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